<DOC>
	<DOCNO>NCT02291419</DOCNO>
	<brief_summary>The purpose pilot study establish rate cardiovascular event patient elevate troponins level major , non-cardiac surgery evaluate efficacy safety FDA approve study drug ( ticagrelor ) compare aspirin patient . Data current study suggest myocardial injury detect minor elevation troponin level within 3 day non-cardiac surgery may occur 10-24 % patient associate increased risk mortality 30 day 1 year . There current guideline care patient elevate troponin level absence acute coronary syndrome . This study ass increase risk patient modifiable anti-platelet medication evaluate safety medication . Patients randomize open label fashion receive ticagrelor ( anti-platelet medication ) 81 mg. aspirin . Patients follow study treatment 12 month , last contact one month post treatment discontinuation .</brief_summary>
	<brief_title>Study Ticagrelor Versus Aspirin Treatment Patients With Myocardial Injury Post Major Non-cardiac Surgery</brief_title>
	<detailed_description>The objective pilot study establish rate cardiovascular event patient elevate troponins level post major , non-cardiac surgery evaluate efficacy safety ticagrelor treatment compare aspirin patient . Data current study suggest myocardial injury detect minor elevation troponin level within 3 day non-cardiac surgery may occur 10-24 % patient associate increased risk mortality 30 day 1 year . There current guideline care patient elevate troponin level absence acute coronary syndrome ( ACS ) certain modifiable disease process . Ticagrelor direct , reversible inhibitor platelet P2Y12ADP-receptor . It show superior clopidogrel set ACS . The clinical benefit treat patient port-operative troponin elevation antiplatelet agent remain unexplored . The short half-life ticagrelor make favorable use setting . This open label , randomize , parallel group study compare ticagrelor aspirin patient experience troponin elevation post major non-cardiac surgery . Patients randomize open-label fashion receive either ticagrelor 90 mg twice daily aspirin 81 mg daily . Patients follow 13 month post randomization ( 12 month treatment phone call 30 day study drug discontinuation ) . The maximum duration treatment 12 month . Follow-up visit occur Month 1 , Month 6 , Month 12 . Phone call make Month 3 , Month 9 , 30 day study drug discontinuation . Up 1000 patient post-operative troponin elevation ≥2x ULN within first 7 postoperative day , enrol study .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Written inform consent study relate procedure perform . 2 . A qualify postoperative T I troponin elevation ( ≥2x ULN assay within 7 day index surgery index hospitalization ) . 3 . Men woman ≥40 year age troponin elevation identify part routine postoperative clinical care OR 4 . Men woman ≥55 year age troponin elevation identify postoperatively part screen study . 5 . Undergone noncardiac surgery require overnight hospital stay . 6 . Women childbearing potential sexually active must negative pregnancy test enrollment agree use adequate contraception screen 30 day receive last dose study drug . 7 . Able randomize within 35 day follow index surgery . 1 . Postoperative STelevation Myocardial Infarction ( STEMI ) . 2 . Postoperative highrisk nonSTEMI , define patient elevate troponin either : 1. active Ischemic EKG change ( ≥2 mm STsegment depression least 2 adjacent lead ) 2. ongoing hemodynamic instability think ischemia mediate 3. persistent anginal symptom . 3 . Planned urgent coronary angiography/revascularization . 4 . A current ongoing indication dual antiplatelet therapy ( DAPT ) determine patient 's physician . 5 . History intracranial hemorrhage 6 . Bleeding disorder active bleeding prevents ticagrelor aspirin administration . 7 . Taking follow medication time randomization : vitamin K antagonist , dabigatran , rivaroxaban , apixaban , edoxaban , fondaparinux , cilostazol , vorapaxar LMWHs . 8 . Renal dialysis . 9 . Hepatic impairment transaminase ≥3x ULN time randomization . 10 . Known contraindication use ticagrelor . 11 . Estimated life expectancy &lt; 1 year . 12 . Enrolled another ongoing drug device research protocol 13 . A definite nonischemic explanation troponin elevation , myocarditis pulmonary embolism . 14 . A documented hypersensitivity aspirin . 15 . Hypersensitivity ticagrelor component product . 16 . Neurological ophthalmic surgery index hospitalization . 17 . Patients take strong CYP3A inhibitor and/or CYP3A inducer stop course study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ticagrelor</keyword>
	<keyword>non-cardiac surgery</keyword>
	<keyword>elevate troponin</keyword>
	<keyword>myocardial injury</keyword>
</DOC>